When will FDA announce Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List?
Prediction markets currently give a 71% probability that When will FDA announce Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List?. This contract trades at 71¢ on Kalshi, closing September 1, 2026. The market is pricing in a 77% probability of FDA reclassification for BPC-157 within 137 days, but the extreme 843% risk-adjusted yield on the No side and 426% realized volatility suggest significant uncertainty despite the high Yes price.
Analysis
The market is pricing in a 77% probability of FDA reclassification for BPC-157 within 137 days, but the extreme 843% risk-adjusted yield on the No side and 426% realized volatility suggest significant uncertainty despite the high Yes price. The sharp 51¢ to 76¢ rally over 7 days combined with thin $124.3 daily volume indicates potential information arrival driving conviction, though low liquidity (Vol Ratio 4.22) means the true consensus may be less bullish than the 77¢ quote suggests. With a Cliff Risk Index of 3 and neutral regime, this appears to be a speculative positioning rather than a settled market view.
Resolution rules
If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Sep 1, 2026, then the market resolves to Yes.
Indicators
Regime
Trade
sf trade KXFDAANNOUNCE-BPC-26SEP01 yes 100